TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-blind, Randomized, Controlled Study to Evaluate Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly (0, 1, 6 Month Schedule) in Healthy Females Aged 18 - 35 Years
Brief Summary: Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women . This study will evaluate the immune response induced by the HPV-16/18 L1 VLP AS04 vaccine and the safety of the vaccine.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1 VLP AS04; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): B
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Arm Label: Boostrix Polio → Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Boostrix ® Polio, Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Arm Label: Cervarix + Boostrix Polio Group; Type: EXPERIMENTAL; Interventions: Biological: Boostrix ® Polio, Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Intervention Type: BIOLOGICAL; Name: Boostrix ® Polio; Assigned to Arm(s): Boostrix Polio → Cervarix Group, Cervarix + Boostrix Polio Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM); Assigned to Arm(s): Boostrix Polio → Cervarix Group, Cervarix + Boostrix Polio Group, Cervarix Group
D: Arm Label: Gardasil®; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Arm Label: Cervarix®; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil® | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix®

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Double-Blinded Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor Between 24 to 32 6/7 Weeks' Gestation
Brief Summary: Primary Hypothesis:

Acute tocolysis (48 hours) using oral nifedipine is more effective than intravenous magnesium sulfate in prolonging pregnancy in women with preterm labor with intact membranes between 24 and 32 6/7 weeks' gestation.


Options:
A: Arm Label: Nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine, Other: Usual care | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Usual care | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Nifedipine, Placebo
B: Arm Label: Atosiban; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
C: Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium sulfate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral Nifedipine or placebo | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oral Nifedipine or placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Brief Summary: Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration. This pilot study of up to 10 eye drop tolerant participants with bilateral geographic atrophy is designed to characterize the effect of 0.45% concentration of OT-551 eye drops given 3 times a day on the progression of geographic atrophy area over a two-year period. Participants will have one eye randomized to receive the eye drop and the fellow eye will be observed only.


Options:
A: N/A
B: Arm Label: OT-551 antioxidant eye drop; Type: EXPERIMENTAL; Interventions: Drug: OT-551 antioxidant eye drop | Intervention Type: DRUG; Name: OT-551 antioxidant eye drop; Assigned to Arm(s): OT-551 antioxidant eye drop
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oseltamivir + zanamivir | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir + zanamivir's placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir's placebo + zanamivir | Intervention Type: DRUG; Name: oseltamivir + zanamivir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oseltamivir + zanamivir's placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: oseltamivir's placebo + zanamivir; Assigned to Arm(s): 3
D: Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes
Brief Summary: This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).


Options:
A: Arm Label: Famciclovir; Type: EXPERIMENTAL; Interventions: Drug: Famciclovir, Drug: Placebo matching valacyclovir | Arm Label: Valacyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valacyclovir, Drug: Placebo matching famciclovir | Intervention Type: DRUG; Name: Famciclovir; Assigned to Arm(s): Famciclovir | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): Valacyclovir | Intervention Type: DRUG; Name: Placebo matching famciclovir; Assigned to Arm(s): Valacyclovir | Intervention Type: DRUG; Name: Placebo matching valacyclovir; Assigned to Arm(s): Famciclovir
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acyclovir | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Acyclovir placebo | Intervention Type: DRUG; Name: Acyclovir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Acyclovir placebo; Assigned to Arm(s): 2
C: Arm Label: Standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: valacyclovir | Arm Label: High-dose; Type: EXPERIMENTAL; Interventions: Drug: acyclovir | Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): High-dose | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): Standard dose
D: Arm Label: valacyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valacyclovir | Arm Label: high dose valacyclovir; Type: EXPERIMENTAL; Interventions: Drug: valacyclovir | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): high dose valacyclovir | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): valacyclovir

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tube Versus Trabeculectomy (TVT) Study
Brief Summary: The purpose of the Tube Versus Trabeculectomy (TVT) Study is to compare the safety and efficacy of nonvalved tube shunt surgery to trabeculectomy with mitomycin C in patients with previous ocular surgery.


Options:
A: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL
B: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
C: Arm Label: Hydrus Aqueous Implant (Treatment); Type: EXPERIMENTAL; Interventions: Device: Hydrus Aqueous Implant | Arm Label: Cataract Surgery (Control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery | Intervention Type: DEVICE; Name: Hydrus Aqueous Implant; Assigned to Arm(s): Hydrus Aqueous Implant (Treatment) | Intervention Type: PROCEDURE; Name: Cataract surgery; Assigned to Arm(s): Cataract Surgery (Control)
D: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tube Versus Trabeculectomy (TVT) Study
Brief Summary: The purpose of the Tube Versus Trabeculectomy (TVT) Study is to compare the safety and efficacy of nonvalved tube shunt surgery to trabeculectomy with mitomycin C in patients with previous ocular surgery.


Options:
A: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
B: Arm Label: Paclitaxel + Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, Drug: Paclitaxel | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel, Paclitaxel + Bevacizumab
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tube Versus Trabeculectomy (TVT) Study
Brief Summary: The purpose of the Tube Versus Trabeculectomy (TVT) Study is to compare the safety and efficacy of nonvalved tube shunt surgery to trabeculectomy with mitomycin C in patients with previous ocular surgery.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Glaucoma Surgery | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: cataract surgery only | Intervention Type: DEVICE; Name: Glaucoma Surgery; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: cataract surgery only; Assigned to Arm(s): 2
B: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
C: Arm Label: iStent; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent | Arm Label: Drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Travoprost | Intervention Type: DEVICE; Name: iStent; Assigned to Arm(s): iStent | Intervention Type: DRUG; Name: Travoprost; Assigned to Arm(s): Drug
D: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tube Versus Trabeculectomy (TVT) Study
Brief Summary: The purpose of the Tube Versus Trabeculectomy (TVT) Study is to compare the safety and efficacy of nonvalved tube shunt surgery to trabeculectomy with mitomycin C in patients with previous ocular surgery.


Options:
A: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL
B: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy
C: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
D: Arm Label: CyPass Micro-Stent + Cataract Surgery; Type: EXPERIMENTAL; Interventions: Procedure: Cataract Surgery, Device: CyPass Micro-Stent | Arm Label: Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract Surgery; Assigned to Arm(s): Cataract Surgery Only, CyPass Micro-Stent + Cataract Surgery | Intervention Type: DEVICE; Name: CyPass Micro-Stent; Assigned to Arm(s): CyPass Micro-Stent + Cataract Surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine and Smoking Cessation in Schizophrenia
Brief Summary: Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
B: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine and Smoking Cessation in Schizophrenia
Brief Summary: Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.


Options:
A: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
B: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine and Smoking Cessation in Schizophrenia
Brief Summary: Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.


Options:
A: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion | Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine and Smoking Cessation in Schizophrenia
Brief Summary: Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II

Answer: D